Well, everybody's realizing that if you go through a PBM, you lose. And when you look at direct-to-patient, whether it's through us, whether it's Trump RX, whether it's Lilly, whether it's Novo Nordisk, whether it's um BMS with Eliquis, whatever it may be, they're doing this to so so that they don't have to deal with the PBMs.
It's really important to have places and physicians and institutions that can meet them where they are. And it's not that I didn't feel like I was doing that in my own office space. It's just that I felt like I could do it better.
